Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 0.71 |
| ▸ | PDE5A | O76074 | 5/20 | 0.71 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.71 |
| ▸ | PDE11A | Q9HCR9 | 5/20 | 0.71 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.71 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.71 |
| ▸ | PDE2A | O00408 | 4/20 | 0.71 |
| ▸ | PDE8A | O60658 | 4/20 | 0.71 |
| ▸ | PDE9A | O76083 | 3/20 | 0.67 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201344 | 0.93 | PDE4A (0.70) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL17366408 | 0.88 | PDE4A (0.84) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL8048554 | 0.88 | PDE4A (0.84) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL3075056 | 0.87 | PDE4A (0.88) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL10201350 | 0.87 | PDE4A (0.79) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL24066896 | 0.87 | PDE4A (0.81) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL3057777 | 0.86 | PDE4A (0.57) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL8052910 | 0.85 | PDE4A (0.79) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL17366407 | 0.85 | PDE4A (0.81) | PDE4APDE5APDE3BPDE11APDE7B | |
| SCHEMBL10201377 | 0.85 | PDE4A (0.81) | PDE4APDE5APDE3BPDE11APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682355-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10183023-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-10010553-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170128453-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-9403836-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403836-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403836-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2939676-A1 | Organic compounds | Intra-Cellular Therapies, Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20140357606-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2014-12-04 | — | — | US | disclosed |
| US-20140357606-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2014-12-04 | — | — | US | disclosed |
| EP-2698160-A2 | Organic compounds | Takeda Pharmaceutical Company Limited (JP) | 2014-02-19 | — | — | EP | disclosed |
| US-8273751-B2 | Organic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273751-B2 | Organic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273751-B2 | Organic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120238589-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120238589-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120238589-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20100273754-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273754-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273754-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682355-B2 | Uses | CNTN1, BDNF, SMPD1 | PDE4A 44/4885PDE5A 14/4885PDE3B 31/4885 |
| US-10183023-B2 | Uses | CNTN1, BDNF, SMPD1 | PDE4A 44/4885PDE5A 14/4885PDE3B 31/4885 |
| US-20170128453-A1 | NOVEL USES | BDNF, CNTN1, DCX | PDE4A 27/4885PDE5A 28/4885PDE3B 53/4885 |
| US-20100273754-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A7 | PDE4A 734/4885PDE5A 406/4885PDE3B 165/4885 |
| US-20140357606-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A7 | PDE4A 734/4885PDE5A 406/4885PDE3B 165/4885 |
| US-10010553-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | PDE4A 2/4885PDE5A 1/4885PDE3B 7/4885 |
| US-20120238589-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A7 | PDE4A 734/4885PDE5A 406/4885PDE3B 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.